12
www.diahome.org Planning the Lifecycle of Safety Evaluation Brenda Crowe, PhD Eli Lilly and Company

Planning the Lifecycle of Safety Evaluation

  • Upload
    mahina

  • View
    16

  • Download
    0

Embed Size (px)

DESCRIPTION

Planning the Lifecycle of Safety Evaluation. Brenda Crowe, PhD Eli Lilly and Company. Conference Program Committee. Brenda Crowe, PhD, Lilly (Co-chair) Wanju Dai, MD, DrPH, sanofi-aventis (Co-chair) Gerald Dal Pan, MD, MHS, FDA Henry “Skip” Francis, MD, FDA - PowerPoint PPT Presentation

Citation preview

Page 1: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Planning the Lifecycle of Safety Evaluation

Brenda Crowe, PhD

Eli Lilly and Company

Page 2: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Conference Program Committee

• Brenda Crowe, PhD, Lilly (Co-chair)• Wanju Dai, MD, DrPH, sanofi-aventis (Co-chair)• Gerald Dal Pan, MD, MHS, FDA• Henry “Skip” Francis, MD, FDA• Paul Huckle, MD, GlaxoSmithKline• Robert O’Neill, PhD, FDA• Manfred Oster, MD, sanofi-aventis• George Rochester, PhD, RAC, FDA• Amy Xia, PhD, Amgen

Program Advisors• Walt Offen, PhD, Lilly• Steve Snapinn, PhD, Lilly

Page 3: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Conference Co-chairpersons

In addition to the program committee:• Howard Chazin, MD, MBA, FDA• Eileen King, PhD, Procter & Gamble• Judith Racoosin, MD, MPH, FDA• James Hung, PhD, FDA• Henry Hsu, PhD, MPH, FDA• Jesse Berlin, ScD, Johnson & Johnson• Sandra Kweder, MD, FDA

Page 4: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Special Thanks

• Constance Burnett, DIA

• Jessica Kusma, DIA

• Debra Michaels, DIA

Page 5: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Conference Goals

• Stimulate discussion among FDA and industry participants regarding proactive planning of safety evaluation throughout the lifecycle of drug development.– Includes planning for data collection,

evaluation (including data monitoring committees), integration, analysis (including meta-analysis) and reporting.

Page 6: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Program Outline—Day 1

• 9:10 – 10:30: Challenges and Opportunities to Improve Premarketing Safety Planning, Evaluation and Reporting

• 11:00 – noon, 1:30 – 2:30: Combining Safety Data at a Development Program Level—Data Collection and Study Design: Dirt Road Vs. Super Highway

• 2:30 – 3:45: How to Improve Safety Data Analysis and Presentation

• 4:15 – 5:30: Safety Boundaries for Data Monitoring Committees

• 5:30 - 6:30: Reception

Page 7: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Program Outline—Day 2

• 8:30 – 8:40: Welcome and Keynote Introduction• 8:40 – 9:30: Keynote Presentation (Janet Woodcock)• 9:30 – 10:30: Introduction and Overview of Meta-

analysis• 11:00 – 12:30: Concurrent sessions (Meta-analysis

of 1. Rare Events and 2. Observational Data)• 1:45 – 3:00: Regulatory Decision Making Based on

Meta-analysis Results• 3:30 – 4:30: Lessons Learned and Path Forward

Panel• 4:35: Conference adjourned

Page 8: Planning the Lifecycle of Safety Evaluation

www.diahome.org

Time• Session chairs:

Please synchronize your watches:It is now: ….9:0X am

• Very important: We need to stick to allotted time

Page 9: Planning the Lifecycle of Safety Evaluation

www.diahome.org

5minute

Page 10: Planning the Lifecycle of Safety Evaluation

www.diahome.org

1minute

Page 11: Planning the Lifecycle of Safety Evaluation

www.diahome.org

0minute

Page 12: Planning the Lifecycle of Safety Evaluation

www.diahome.org

-1minute

Stop Now!! Please

You’re killing me!